MX2023000008A - Inhibidor de fgfr y mutacion, metodo de preparacion y uso del mismo. - Google Patents
Inhibidor de fgfr y mutacion, metodo de preparacion y uso del mismo.Info
- Publication number
- MX2023000008A MX2023000008A MX2023000008A MX2023000008A MX2023000008A MX 2023000008 A MX2023000008 A MX 2023000008A MX 2023000008 A MX2023000008 A MX 2023000008A MX 2023000008 A MX2023000008 A MX 2023000008A MX 2023000008 A MX2023000008 A MX 2023000008A
- Authority
- MX
- Mexico
- Prior art keywords
- fgfr
- preparation
- method therefor
- inhibitor
- mutation inhibitor
- Prior art date
Links
- 230000035772 mutation Effects 0.000 title abstract 5
- 238000002360 preparation method Methods 0.000 title abstract 5
- 239000003112 inhibitor Substances 0.000 title abstract 4
- 108091008794 FGF receptors Proteins 0.000 abstract 5
- 102000052178 fibroblast growth factor receptor activity proteins Human genes 0.000 abstract 5
- 206010028980 Neoplasm Diseases 0.000 abstract 4
- 239000003814 drug Substances 0.000 abstract 2
- 229940079593 drug Drugs 0.000 abstract 2
- 239000004118 Natrolite-phonolite Substances 0.000 abstract 1
- 229940125829 fibroblast growth factor receptor inhibitor Drugs 0.000 abstract 1
- 230000001404 mediated effect Effects 0.000 abstract 1
- 239000008194 pharmaceutical composition Substances 0.000 abstract 1
- 230000019491 signal transduction Effects 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
- C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
- C07D487/04—Ortho-condensed systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/4985—Pyrazines or piperazines ortho- or peri-condensed with heterocyclic ring systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
- A61K31/52—Purines, e.g. adenine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/53—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with three nitrogens as the only ring hetero atoms, e.g. chlorazanil, melamine
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D473/00—Heterocyclic compounds containing purine ring systems
- C07D473/26—Heterocyclic compounds containing purine ring systems with an oxygen, sulphur, or nitrogen atom directly attached in position 2 or 6, but not in both
- C07D473/32—Nitrogen atom
- C07D473/34—Nitrogen atom attached in position 6, e.g. adenine
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D519/00—Heterocyclic compounds containing more than one system of two or more relevant hetero rings condensed among themselves or condensed with a common carbocyclic ring system not provided for in groups C07D453/00 or C07D455/00
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Pharmacology & Pharmacy (AREA)
- Medicinal Chemistry (AREA)
- Animal Behavior & Ethology (AREA)
- Epidemiology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Nitrogen Condensed Heterocyclic Rings (AREA)
- Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Medicines Containing Material From Animals Or Micro-Organisms (AREA)
Abstract
Se proporciona un inhibidor de FGFR y mutación del mismo, y un método de preparación y uso del mismo. En particular, se proporciona un inhibidor de FGFR y mutación que tiene una estructura de fórmula (I), un método de preparación del mismo, una composición farmacéutica que contiene el mismo, el uso del mismo como un inhibidor de FGFR y mutación del mismo y el uso del mismo en la preparación de un fármaco para tratar y/o prevenir un tumor o cáncer mediado, al menos en parte, por una cinasa de FGFR y para tratar a un paciente con un tumor que tiene resistencia a un inhibidor de FGFR, en particular, el uso del mismo en la preparación de un fármaco para tratar y/o prevenir un tumor en un paciente con mutaciones en V561, V565, N550, N540, V555, E566, K660 y/o V550 de una vía de señalización de FGFR. Cada sustituyente de fórmula (I) tiene la misma definición que en la descripción. (ver Fórmula).
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN202010811490 | 2020-08-13 | ||
| PCT/CN2021/112121 WO2022033532A1 (zh) | 2020-08-13 | 2021-08-11 | 一种fgfr及其突变抑制剂，其制备方法和应用 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| MX2023000008A true MX2023000008A (es) | 2023-01-30 |
Family
ID=80246991
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| MX2023000008A MX2023000008A (es) | 2020-08-13 | 2021-08-11 | Inhibidor de fgfr y mutacion, metodo de preparacion y uso del mismo. |
Country Status (10)
| Country | Link |
|---|---|
| US (1) | US20230303575A1 (es) |
| EP (1) | EP4169922A4 (es) |
| KR (1) | KR20230015419A (es) |
| CN (1) | CN115485281B (es) |
| AU (1) | AU2021323844B2 (es) |
| BR (1) | BR112022026386A2 (es) |
| CA (1) | CA3184247A1 (es) |
| MX (1) | MX2023000008A (es) |
| TW (1) | TWI797711B (es) |
| WO (1) | WO2022033532A1 (es) |
Families Citing this family (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN116096707A (zh) * | 2020-06-05 | 2023-05-09 | 金耐特生物制药公司 | 成纤维细胞生长因子受体激酶的抑制剂 |
| CN115785103A (zh) * | 2022-12-28 | 2023-03-14 | 北京康立生医药技术开发有限公司 | 一种治疗胆管癌药物福巴替尼的合成方法 |
Family Cites Families (8)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US7659274B2 (en) * | 2006-01-25 | 2010-02-09 | Osi Pharmaceuticals, Inc. | Unsaturated mTOR inhibitors |
| AU2013210403B2 (en) * | 2012-01-19 | 2016-01-14 | Taiho Pharmaceutical Co., Ltd. | 3,5-disubstituted alkynylbenzene compound and salt thereof |
| DK3023100T3 (da) * | 2013-07-18 | 2019-05-27 | Taiho Pharmaceutical Co Ltd | Antitumorlægemiddel til intermitterende administration af fgfr-hæmmer |
| ES2819398T3 (es) * | 2013-07-18 | 2021-04-15 | Taiho Pharmaceutical Co Ltd | Agente terapéutico para el cáncer resistente al inhibidor de FGFR |
| CN105461720B (zh) * | 2014-08-08 | 2019-08-06 | 南京圣和药业股份有限公司 | 吗啉类酪氨酸激酶抑制剂 |
| CN107344940B (zh) * | 2016-05-06 | 2020-04-21 | 广东东阳光药业有限公司 | Btk抑制剂及其用途 |
| CN109776544B (zh) * | 2017-11-15 | 2022-02-01 | 上海医药工业研究院 | 吡唑并[3,4-d]嘧啶类化合物及其制备方法和用途 |
| CN116096707A (zh) * | 2020-06-05 | 2023-05-09 | 金耐特生物制药公司 | 成纤维细胞生长因子受体激酶的抑制剂 |
-
2021
- 2021-08-10 TW TW110129491A patent/TWI797711B/zh active
- 2021-08-11 US US18/014,095 patent/US20230303575A1/en active Pending
- 2021-08-11 CA CA3184247A patent/CA3184247A1/en active Pending
- 2021-08-11 BR BR112022026386A patent/BR112022026386A2/pt unknown
- 2021-08-11 EP EP21855583.7A patent/EP4169922A4/en active Pending
- 2021-08-11 MX MX2023000008A patent/MX2023000008A/es unknown
- 2021-08-11 WO PCT/CN2021/112121 patent/WO2022033532A1/zh active Application Filing
- 2021-08-11 AU AU2021323844A patent/AU2021323844B2/en active Active
- 2021-08-11 CN CN202180032537.4A patent/CN115485281B/zh active Active
- 2021-08-11 KR KR1020227045000A patent/KR20230015419A/ko active Search and Examination
Also Published As
| Publication number | Publication date |
|---|---|
| WO2022033532A1 (zh) | 2022-02-17 |
| KR20230015419A (ko) | 2023-01-31 |
| CA3184247A1 (en) | 2022-02-17 |
| TWI797711B (zh) | 2023-04-01 |
| AU2021323844A1 (en) | 2023-01-19 |
| AU2021323844B2 (en) | 2023-07-27 |
| EP4169922A4 (en) | 2024-03-13 |
| CN115485281B (zh) | 2023-11-21 |
| EP4169922A1 (en) | 2023-04-26 |
| CN115485281A (zh) | 2022-12-16 |
| JP2023530768A (ja) | 2023-07-19 |
| TW202206433A (zh) | 2022-02-16 |
| BR112022026386A2 (pt) | 2023-02-23 |
| US20230303575A1 (en) | 2023-09-28 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CR20220584A (es) | Inhibidores de kras tricíclicos fusionados | |
| WO2020093006A8 (en) | Methods of treating cancer in biomarker-identified patients with non-covalent inhibitors of cyclin-dependent kinase 7 (cdk7) | |
| GEP20227433B (en) | 2-amino-pyridine or 2-amino-pyrimidine derivatives as cyclin dependent kinase inhibitors | |
| CR20230165A (es) | Derivados indólicos como inhibidores de ras en el tratamiento del cáncer | |
| O'Shaughnessy et al. | Commentary concerning demonstration of safety and efficacy of investigational anticancer agents in clinical trials. | |
| MX2023000008A (es) | Inhibidor de fgfr y mutacion, metodo de preparacion y uso del mismo. | |
| BR112019007143A2 (pt) | compostos de pirazolo[1,5-a]piridina substituídos como inibidores da ret cinase | |
| MY183036A (en) | Amino-triazolopyridine compounds and their use in treating cancer | |
| BR112021024674A2 (pt) | Derivado heterocíclico de nitrogênio com cinco membros de pirimidina, método de preparação do mesmo e uso farmacêutico do mesmo | |
| Barnaba et al. | Targeting cell cycle regulation via the G2-M checkpoint for synthetic lethality in melanoma | |
| Liu et al. | β-elemene enhances both radiosensitivity and chemosensitivity of glioblastoma cells through the inhibition of the ATM signaling pathway | |
| WO2018141002A3 (en) | DERIVATIVES OF N-CYCLOALKYL/HETEROCYCLOALKYL-4-(IMIDAZO [1,2-a]PYRIDINE)PYRIMIDIN-2-AMINE AS THERAPEUTIC AGENTS | |
| PL2324008T3 (pl) | 3,4-diarylopirazole jako inhibitory kinazy białkowej | |
| Otręba et al. | In vitro anticancer activity of fluphenazine, perphenazine and prochlorperazine. A review | |
| UA94097C2 (ru) | Пиридил- и пиримидинилзамещенные производной пиррола, тиофена и фурана как ингибиторы киназ | |
| EA033284B1 (ru) | ПРОИЗВОДНЫЕ 8-[6-[3-(АМИНО)ПРОПОКСИ]-3-ПИРИДИЛ]-1-ИЗОПРОПИЛ-ИМИДАЗО[4,5-c]ХИНОЛИН-2-ОНА В КАЧЕСТВЕ СЕЛЕКТИВНЫХ МОДУЛЯТОРОВ КИНАЗЫ МУТАЦИИ АТАКСИИ-ТЕЛЕАНГИЭКТАЗИИ (ATM) ДЛЯ ЛЕЧЕНИЯ РАКА | |
| RU2011142806A (ru) | Комбинации пентамидина для лечения рака | |
| BR112016028641A2 (pt) | ?método para tratar câncer? | |
| TN2010000204A1 (en) | Kinesin inhibitors as cancer therapeutics | |
| PH12020551851A1 (en) | Treatment of cancers having driving oncogenic mutations | |
| MX2020012347A (es) | Inhibidor que contiene derivado triciclico, metodo de preparacion del mismo y aplicacion del mismo. | |
| Yin et al. | Targeting human MutT homolog 1 (MTH1) for cancer eradication: current progress and perspectives | |
| FR2921927B1 (fr) | Imidazo°1,2-a!quinoxalines et derives pour le traitement des cancers | |
| CR20240059A (es) | Compuestos tricíclicos como inhibidores de kras. | |
| MX2021009426A (es) | Derivados de indazolil-isoxazol para el tratamiento de enfermedades tales como cancer. |